Pulmonx Corporation (LUNG) |
|
11.18 0.21 (1.91%)
|
03-31 16:00 |
|
Open: |
11.05 |
Pre. Close: |
10.97 |
|
High:
|
11.28 |
Low:
|
10.88 |
|
Volume:
|
671,091 |
Market Cap:
|
421(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:20:17 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 13.88 One year: 14.92 |
| Support: |
Support1: 10.43 Support2: 8.68 |
| Resistance: |
Resistance1: 11.88 Resistance2: 12.77 |
| Pivot: |
11.36 |
| Moving Average: |
MA(5): 10.94 MA(20): 11.38 
MA(100): 8.55 MA(250): 14.45 |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.3 |
| Stochastic oscillator: |
%K(14,3): 25 %D(3): 19.1 |
| RSI: |
RSI(14): 52.5 |
| 52-week: |
High: 28.29 Low: 4.07 |
| Average Vol(K): |
3-Month: 509 (K) 10-Days: 458 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LUNG ] has closed above bottom band by 40.8%. Bollinger Bands are 43.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.29 - 11.34 |
11.34 - 11.38 |
|
Low:
|
10.77 - 10.82 |
10.82 - 10.87 |
|
Close:
|
11.1 - 11.18 |
11.18 - 11.26 |
|
Company Description |
|
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. |
Headline News |
Thu, 16 Mar 2023
Pulmonx Co. (NASDAQ:LUNG) Receives Average Rating of ... - MarketBeat
Tue, 14 Mar 2023
50174 Shares in Pulmonx Co. (NASDAQ:LUNG) Acquired by ... - MarketBeat
Fri, 24 Feb 2023
Why Shares of Pulmonx Rose This Week - The Motley Fool
Wed, 22 Feb 2023
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Wed, 22 Feb 2023
Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results - GlobeNewswire
Wed, 30 Nov 2022
Pulmonx Receives Japanese MHLW Approval of Zephyr ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
37 (M) |
| Shares Float |
30 (M) |
|
% Held by Insiders
|
3.6 (%) |
|
% Held by Institutions
|
105.9 (%) |
|
Shares Short
|
2,950 (K) |
|
Shares Short P.Month
|
2,940 (K) |
Stock Financials |
|
EPS
|
-2 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
6.11 |
|
Profit Margin (%)
|
-111 |
|
Operating Margin (%)
|
-108.6 |
|
Return on Assets (ttm)
|
-15.7 |
|
Return on Equity (ttm)
|
-31.5 |
|
Qtrly Rev. Growth
|
1.7 |
|
Gross Profit (p.s.)
|
0.95 |
|
Sales Per Share
|
1.38 |
|
EBITDA (p.s.)
|
-1.47 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-46 (M) |
|
Levered Free Cash Flow
|
-23 (M) |
Stock Valuations |
|
PE Ratio
|
-5.6 |
|
PEG Ratio
|
-0.3 |
|
Price to Book value
|
1.82 |
|
Price to Sales
|
8.05 |
|
Price to Cash Flow
|
-9.1 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
